Table I.
Demographics of the prostate cancer samples.
| Clinicopathological parameters | Value |
|---|---|
| Age in years, n (%) | |
| <50 | 9 (13.2) |
| 50–59 | 38 (55.9) |
| >60 | 21 (30.9) |
| Pretreatment PSA in ng/ml, n (%) | |
| <4 | 8 (11.8) |
| 4–10 | 31 (45.6) |
| 10–20 | 18 (26.5) |
| >20 | 5 (7.4) |
| Tumor volume %, n (%) | |
| <5 | 19 (27.9) |
| 5–10 | 13 (19.1) |
| 10–20 | 12 (17.6) |
| 20–50 | 14 (20.6) |
| >50 | 4 (5.9) |
| Gleason score, n (%) | |
| <7 | 19 (27.9) |
| =7 | 36 (52.9) |
| >7 | 13 (19.1) |
| pT stagea, n (%) | |
| pT2 | 38 (55.9) |
| pT3 | 30 (44.1) |
| Surgical margin, n (%) | |
| Negative | 46 (67.6) |
| Positive | 22 (32.4) |
| Lymphovascular invasion, n (%) | |
| Absent | 54 (79.4) |
| Present | 14 (20.6) |
| Perineural invasion, n (%) | |
| Absent | 37 (54.4) |
| Present | 31 (45.6) |
| Metastasis, n (%) | |
| Absent | 57 (83.8) |
| Present | 5 (7.4) |
| Biochemical recurrence, n (%) | |
| Absent | 45 (66.2) |
| Present | 17 (25.0) |
| Mortality, n (%) | |
| Alive | 59 (86.8) |
| Succumbed | 9 (13.2) |
| Follow-up, months | |
| Range | 11–111 |
| Mean | 49.2 |
a
American Joint Committee on Cancer 2010 criteria. pT stage, pathological T stage; PSA, prostatic-specific antigen.